Open Access
ARTICLE
Exogenous dendritic cells aggravate atherosclerosis via P-selectin/ PSGL-1 pathway
LEI ZHONG1, LEI GUO1, ZHISHUAI YE2, SHANFENG ZHANG3, RONGCHONG HUANG2,*
1 Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China
2 Cardiac Center/Division of Cardiovascular Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China
3 Dalian Medical University, Dalian Medical University, Dalian, 116044, China
* Address correspondence to: Rongchong Huang,
BIOCELL 2020, 44(2), 225-236. https://doi.org/10.32604/biocell.2020.08714
Received 03 October 2019; Accepted 25 January 2020; Issue published 27 May 2020
Abstract
Studies have found that a large number of inflammatory cells, P-selectin, and mature dendritic cells (DCs) are
expressed in the damaged and shoulder parts of atherosclerotic plaque, which demonstrates that P-selectin and mature
DCs participate in the immune inflammatory response leading to the development of atherosclerosis. However, it is
unclear how the above factors interact in this setting. In this study, we investigated the role of P-selectin and its
receptor, P-selectin glycoprotein ligand (PSGL)-1 in atherosclerosis, with the finding that DC surface marker
expression was consistently high in the P-selectin group while consistently low in the PGSL-1 + DCs group, with
CD40 and CD86 expressed by 3.84% and 2.05% for the latter. The highest expression of CD80, CD83, and MHC II
was discovered in the DC group, at 7.49%, 3.68%, and 8.98%, respectively. Results of this study are similar to those
obtained previously by
Ye et al. (2017), which showed larger atherosclerotic lesions in mice that received exogenous
DCs, compared with those treated with PBS. In this study, the greatest level of atherosclerosis, fibrosis, and lipid
deposition was also seen in mice that received exogenous DCs.
Keywords
Cite This Article
ZHONG, L., GUO, L., YE, Z., ZHANG, S., HUANG, R. (2020). Exogenous dendritic cells aggravate atherosclerosis via P-selectin/ PSGL-1 pathway.
BIOCELL, 44(2), 225–236.